Preferred Label : Bortezomib/Daratumumab/Dexamethasone/Lenalidomide Regimen;

NCIt synonyms : Bortezomib/Daratumumab/Dexamethasone/Lenalidomide; Daratumumab-RVD; RVD Regimen Plus Daratumumab; Darzalex-RVD; D-RVD Regimen; Bortezomib-Lenalidomide-Dexamethasone Plus Daratumumab; Bortezomib/Lenalidomide/Dexamethasone Plus Daratumumab; Bortezomib/Lenalidomide/Dexamethasone Plus Daratumumab Regimen; Bortezomib-Daratumumab-Dexamethasone-Lenalidomide; Velcade/Revlimid/Dexamethasone-Darzalex; Bortezomib-Daratumumab-Dexamethasone-Lenalidomide Regimen; RVD Plus Darzalex; Dara-RVd;

NCIt definition : A regimen consisting of bortezomib, daratumumab, dexamethasone and lenalidomide that can be used for the treatment of plasma cell (multiple) myeloma.;

NCI Metathesaurus CUI : CL1664476;

Codes from synonyms : 6472;

Détails


Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :


https://www.has-sante.fr/jcms/p_3610014/fr/darzalex-daratumumab-myelome-multiple
2025
false
false
false
France
antineoplastic combined chemotherapy protocols
treatment outcome
insurance, health, reimbursement
Bortezomib/Daratumumab/Dexamethasone/Lenalidomide Regimen
Bortezomib
dexamethasone
Lenalidomide
antineoplastic agents
daratumumab
hematopoietic stem cell transplantation
transplantation, autologous
evaluation of the transparency committee
multiple myeloma
daratumumab

---
Nous contacter.
30/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.